Developer docs
API playgroundTry for free, no card

Search company profiles

Coiled Therapeutics

Full company profile

uuid0009caj

Namestring
Coiled Therapeutics
Legal namestring
Coiled Therapeutics plc
Websiteurl
coiledplc.com
Company typeenum
Public
Founded yearint
2025
Descriptiontext

Coiled Therapeutics plc is a clinical-stage precision oncology company developing first-in-class therapeutics for high-risk cancers. It was spun out from A2A Pharmaceuticals, Inc. in 2025 and completed a reverse takeover of Roquefort Therapeutics in March 2026 to acquire exclusive worldwide rights to its lead asset, AO-252 — a first-in-class, oral, brain-penetrant small molecule inhibitor of TACC3 (Transforming Acidic Coiled-Coil Containing Protein 3). AO-252 is currently in a Phase I clinical trial (NCT06136884) in the United States, with encouraging early clinical activity reported in ovarian and endometrial cancer patients, and the company is targeting material data readouts by Q4 2026 to support expansion cohorts in prostate and ovarian cancer and to enable partnering discussions with major pharmaceutical companies. The company leverages the proprietary SCULPT AI/ML-driven de novo drug design platform inherited from A2A Pharmaceuticals to discover and optimise compounds against coiled-coil and other structurally complex oncogenic proteins.

The company's broader pipeline includes a STAT-6 targeted siRNA programme for Th2-driven inflammatory conditions such as asthma, fibrosis, eczema, and allergic disease, representing a dual indication strategy spanning oncology and immunology. Business model mechanics are those of a pre-revenue clinical-stage biopharma: there are no commercial products, pricing is not applicable, and future revenue is expected to derive from licensing AO-252 and potentially the STAT-6 programme to pharmaceutical partners following clinical proof-of-concept. The company is incorporated in England as Coiled Therapeutics plc, headquartered in London, listed on the London Stock Exchange AIM market under ticker COIL, and cross-traded on the US OTCQB Venture Market under ticker COTXF, with a market capitalisation of approximately £43.15 million as of 24 June 2026.

Short descriptiontext

Coiled Therapeutics plc is a clinical-stage precision oncology company developing AO-252, a first-in-class oral brain-penetrant TACC3 inhibitor in Phase I trials for solid tumours, alongside a STAT-6 siRNA programme for inflammatory diseases, using an AI/ML-driven drug design platform spun out from A2A Pharmaceuticals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology therapeutics, cancer drug development, AI drug discovery, small molecule inhibitors, clinical-stage biopharmaceuticals
Industry3 codes
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Precision Oncology Therapeutics
No data
Revenue model1 record
1Pre-Revenue / Pipeline Development
TypeOne Time License
Description

Clinical-stage oncology company with no commercial products or revenue. Revenue generation is contingent on successful clinical development and regulatory approval of AO-252 and the STAT-6 programme. Future revenue streams may include product sales, licensing agreements, and partnerships with pharmaceutical companies.

coiledplc.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Coiled Therapeutics is a clinical-stage precision oncology company developing first-in-class therapeutics targeting TACC3 and STAT-6 for high-risk cancers and inflammatory diseases. Its lead asset AO-252 is an oral brain-penetrant small molecule TACC3 inhibitor currently in Phase I clinical trials (NCT06136884) for solid tumors including ovarian, breast, prostate, lung, gastric, endometrial, sarcoma, and bladder cancers. The pipeline is supported by the proprietary SCULPT AI/ML-driven de novo drug design platform licensed from A2A Pharmaceuticals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase I clinical trial active with encouraging early clinical activity observed in ovarian and endometrial patients
+2 more records
Product overview1 text field

Coiled Therapeutics is a clinical-stage precision oncology company advancing a pipeline of first-in-class therapeutics for high-risk cancers. The company's core portfolio consists of two programs: AO-252, a first-in-class TACC3 inhibitor currently in Phase I clinical trials for advanced solid tumours, and the STAT-6 program targeting immunology indications using siRNA technology. The company leverages AI/ML-driven de novo drug design platforms developed by A2A Pharmaceuticals to discover and develop therapeutics targeting coiled-coil and structurally complex oncogenic targets.

Product and service2 records
1AO-252
CategoryPrecision Oncology Lead Candidate
Description

First-in-class oral brain-penetrant small molecule inhibitor of TACC3 (Transforming Acidic Coiled-Coil Containing Protein 3) currently in Phase I clinical trials (NCT06136884) for the treatment of advanced solid tumors including ovarian, breast, prostate, lung, gastric, endometrial, sarcoma, and bladder cancers. AO-252 triggers severe DNA damage leading to cytoplasmic DNA leakage and activation of innate immune responses via the cGAS/STING pathway, while inhibiting multiple protein-protein interactions including DNA-PK, PARP1, BRCA, KU70, KIFC1, MBD2, and HDAC2.

2STAT-6 Program
CategoryImmunology Pipeline Program
Description

STAT-6 targeted program using siRNA technology for immunology indications including asthma, fibrosis, eczema, and allergic disease. Differentiated approach to inhibit IL-4/IL-13 signalling and Th2 differentiation, offering advantages over existing upstream therapies such as Dupixent.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Professor Guru Sonpavde
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-17
Description

Appointed to newly formed Medical Advisory Board to guide lead drug candidate AO-252 through early-stage Phase I human trials. Professor Sonpavde is an oncology heavyweight bringing extensive clinical trial experience and will shape clinical strategy including expansion cohort design, indication selection, and combination therapy plans.

proactiveinvestors.co.uk
2Dr Alexander Spira
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-17
Description

Appointed to newly formed Medical Advisory Board to guide lead drug candidate AO-252 through early-stage Phase I human trials. Dr Spira is an oncology expert who will contribute to clinical strategy including expansion cohort design, indication selection, and combination therapy plans.

proactiveinvestors.co.uk
3Ozgur Sahin
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-08
Description

Appointed as Scientific Advisor to provide expertise in support of the company's scientific and clinical development programmes.

coiledplc.com
4Roquefort Therapeutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

Roquefort Therapeutics completed a reverse takeover with Coiled Therapeutics, Inc. resulting in Roquefort being renamed Coiled Therapeutics plc. The transaction valued at approximately £32 million in shares plus £8.5 million placing involved Roquefort acquiring exclusive worldwide rights to AO-252. The company is now listed on AIM under ticker COIL.

dailymail.co.uk
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Coiled Therapeutics was spun out from A2A Pharmaceuticals in 2025. The company leverages A2A's proprietary AI/ML-driven de novo design platform called SCULPT. The worldwide license to AO-252 was acquired from Coiled Therapeutics, Inc., a spin-out of A2A Pharmaceuticals, and Chaemin Lim, PhD, a founding team member and former CSO at A2A Pharmaceuticals, now serves as Chief Technology Officer at Coiled Therapeutics.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision oncology biotech targeting chromatin biology and protein-protein interactions, including coiled-coil and structurally complex targets. Highly comparable to Coiled's approach against undruggable oncogenic proteins and its platform-based discovery model.

TypeDirect peer
Description

Clinical-stage precision oncology company developing allosteric and mutation-targeted small molecules against historically difficult oncology targets. Comparable to Coiled in scale, development stage, and first-in-class precision oncology positioning.

TypeDirect peer
Description

Clinical-stage precision oncology company combining computational approaches with structure-based drug design against precision oncology targets, including protein motion-based design. Comparable to Coiled's AI/ML-driven design philosophy against complex targets.

TypeDirect peer
Description

Clinical-stage precision oncology company targeting synthetic lethal vulnerabilities in cancer using a platform-based discovery approach. Comparable in clinical-stage precision oncology positioning, multi-indication strategy, and platform-driven pipeline development.

TypeDirect peer
Description

Clinical-stage precision oncology company developing targeted therapies against oncogenic drivers with a focus on smaller, indication-focused trials and partnering optionality. Comparable to Coiled's clinical-stage, indication-specific development strategy.

TypeDirect peer
Description

Clinical-stage precision oncology company developing small molecule inhibitors targeting the RAS/MAPK pathway. Comparable as a clinical-stage precision oncology peer with multiple programmes and a focus on historically difficult-to-drug oncogenic targets.

TypeBroad incumbent
Description

Computational drug discovery company combining physics-based modelling with AI/ML for small molecule discovery across multiple therapeutic areas. Comparable to Coiled's use of computational and AI-driven drug design for structurally complex targets, though Schrödinger operates at much greater scale and breadth.

TypeBroad incumbent
Description

AI-driven drug discovery platform combining high-throughput biology with machine learning for pharmaceutical R&D. Comparable to Coiled's AI/ML-driven discovery philosophy, though operating at much broader scale and across multiple therapeutic areas.

TypeBroad incumbent
Description

AI-driven precision medicine company using end-to-end AI platforms for small molecule drug discovery. Comparable to Coiled's AI/ML-driven de novo design approach, though Exscientia operates at greater scale with broader pipeline and partner network.

TypeEmerging player
Description

Leading siRNA therapeutics company with multiple approved and clinical-stage RNA interference products across rare and specialty diseases. Comparable to Coiled's STAT-6 siRNA programme as the most established peer in the siRNA modality space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Coiled Therapeutics

Precision Oncology Therapeuticscoiledplc.com

Coiled Therapeutics plc is a clinical-stage precision oncology company developing AO-252, a first-in-class oral brain-penetrant TACC3 inhibitor in Phase I trials for solid tumours, alongside a STAT-6 siRNA programme for inflammatory diseases, using an AI/ML-driven drug design platform spun out from A2A Pharmaceuticals.

What Coiled Therapeutics does

Coiled Therapeutics plc is a clinical-stage precision oncology company developing first-in-class therapeutics for high-risk cancers. It was spun out from A2A Pharmaceuticals, Inc. in 2025 and completed a reverse takeover of Roquefort Therapeutics in March 2026 to acquire exclusive worldwide rights to its lead asset, AO-252 — a first-in-class, oral, brain-penetrant small molecule inhibitor of TACC3 (Transforming Acidic Coiled-Coil Containing Protein 3). AO-252 is currently in a Phase I clinical trial (NCT06136884) in the United States, with encouraging early clinical activity reported in ovarian and endometrial cancer patients, and the company is targeting material data readouts by Q4 2026 to support expansion cohorts in prostate and ovarian cancer and to enable partnering discussions with major pharmaceutical companies. The company leverages the proprietary SCULPT AI/ML-driven de novo drug design platform inherited from A2A Pharmaceuticals to discover and optimise compounds against coiled-coil and other structurally complex oncogenic proteins.

The company's broader pipeline includes a STAT-6 targeted siRNA programme for Th2-driven inflammatory conditions such as asthma, fibrosis, eczema, and allergic disease, representing a dual indication strategy spanning oncology and immunology. Business model mechanics are those of a pre-revenue clinical-stage biopharma: there are no commercial products, pricing is not applicable, and future revenue is expected to derive from licensing AO-252 and potentially the STAT-6 programme to pharmaceutical partners following clinical proof-of-concept. The company is incorporated in England as Coiled Therapeutics plc, headquartered in London, listed on the London Stock Exchange AIM market under ticker COIL, and cross-traded on the US OTCQB Venture Market under ticker COTXF, with a market capitalisation of approximately £43.15 million as of 24 June 2026.

Coiled Therapeutics firmographics

Firmographics
Name
Coiled Therapeutics
Legal name
Coiled Therapeutics plc
Website
https://coiledplc.com
Company type
Public
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Short description
Coiled Therapeutics plc is a clinical-stage precision oncology company developing AO-252, a first-in-class oral brain-penetrant TACC3 inhibitor in Phase I trials for solid tumours, alongside a STAT-6 siRNA programme for inflammatory diseases, using an AI/ML-driven drug design platform spun out from A2A Pharmaceuticals.
Ownership category
akta.pro rank

Coiled Therapeutics industry classification

Industry
Product category
Precision Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Precision oncology therapeutics
  • Cancer drug development
  • AI drug discovery
  • Small molecule inhibitors
  • Clinical-stage biopharmaceuticals

Where Coiled Therapeutics is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices6 records

Markets served

Coiled Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pre-Revenue / Pipeline Development: Clinical-stage oncology company with no commercial products or revenue. Revenue generation is contingent on successful clinical development and regulatory approval of AO-252 and the STAT-6 programme. Future revenue streams may include product sales, licensing agreements, and partnerships with pharmaceutical companies.

Distribution channels1 record

Marketing channels4 records

Coiled Therapeutics product offering

Product offering

Core offering

Coiled Therapeutics is a clinical-stage precision oncology company developing first-in-class therapeutics targeting TACC3 and STAT-6 for high-risk cancers and inflammatory diseases. Its lead asset AO-252 is an oral brain-penetrant small molecule TACC3 inhibitor currently in Phase I clinical trials (NCT06136884) for solid tumors including ovarian, breast, prostate, lung, gastric, endometrial, sarcoma, and bladder cancers. The pipeline is supported by the proprietary SCULPT AI/ML-driven de novo drug design platform licensed from A2A Pharmaceuticals.

Product overview

Coiled Therapeutics is a clinical-stage precision oncology company advancing a pipeline of first-in-class therapeutics for high-risk cancers. The company's core portfolio consists of two programs: AO-252, a first-in-class TACC3 inhibitor currently in Phase I clinical trials for advanced solid tumours, and the STAT-6 program targeting immunology indications using siRNA technology. The company leverages AI/ML-driven de novo drug design platforms developed by A2A Pharmaceuticals to discover and develop therapeutics targeting coiled-coil and structurally complex oncogenic targets.

Differentiator

Problem solved

Functional benefit

Products and services

  • AO-252 First-in-class oral brain-penetrant small molecule inhibitor of TACC3 (Transforming Acidic Coiled-Coil Containing Protein 3) currently in Phase I clinical trials (NCT06136884) for the treatment of advanced solid tumors including ovarian, breast, prostate, lung, gastric, endometrial, sarcoma, and bladder cancers. AO-252 triggers severe DNA damage leading to cytoplasmic DNA leakage and activation of innate immune responses via the cGAS/STING pathway, while inhibiting multiple protein-protein interactions including DNA-PK, PARP1, BRCA, KU70, KIFC1, MBD2, and HDAC2.
  • STAT-6 Program STAT-6 targeted program using siRNA technology for immunology indications including asthma, fibrosis, eczema, and allergic disease. Differentiated approach to inhibit IL-4/IL-13 signalling and Th2 differentiation, offering advantages over existing upstream therapies such as Dupixent.

Quantifiable outcome

  • Phase I clinical trial active with encouraging early clinical activity observed in ovarian and endometrial patients
  • +2 more outcomes

Companies that use Coiled Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Coiled Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Coiled Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Professor Guru SonpavdecoreStrategic or Co-development Partner · 17 June 2026Appointed to newly formed Medical Advisory Board to guide lead drug candidate AO-252 through early-stage Phase I human trials. Professor Sonpavde is an oncology heavyweight bringing extensive clinical trial experience and will shape clinical strategy including expansion cohort design, indication selection, and combination therapy plans.
  • Dr Alexander SpiracoreStrategic or Co-development Partner · 17 June 2026Appointed to newly formed Medical Advisory Board to guide lead drug candidate AO-252 through early-stage Phase I human trials. Dr Spira is an oncology expert who will contribute to clinical strategy including expansion cohort design, indication selection, and combination therapy plans.
  • Ozgur SahincoreStrategic or Co-development Partner · 8 June 2026Appointed as Scientific Advisor to provide expertise in support of the company's scientific and clinical development programmes.
  • Roquefort TherapeuticscoreStrategic or Co-development Partner · 1 March 2026Roquefort Therapeutics completed a reverse takeover with Coiled Therapeutics, Inc. resulting in Roquefort being renamed Coiled Therapeutics plc. The transaction valued at approximately £32 million in shares plus £8.5 million placing involved Roquefort acquiring exclusive worldwide rights to AO-252. The company is now listed on AIM under ticker COIL.
  • A2A Pharmaceuticals, Inc.coreStrategic or Co-development Partner · 1 January 2025Coiled Therapeutics was spun out from A2A Pharmaceuticals in 2025. The company leverages A2A's proprietary AI/ML-driven de novo design platform called SCULPT. The worldwide license to AO-252 was acquired from Coiled Therapeutics, Inc., a spin-out of A2A Pharmaceuticals, and Chaemin Lim, PhD, a founding team member and former CSO at A2A Pharmaceuticals, now serves as Chief Technology Officer at Coiled Therapeutics.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Coiled Therapeutics competitors and assessment

Company assessment

Direct peers

  • Foghorn Therapeutics: Clinical-stage precision oncology biotech targeting chromatin biology and protein-protein interactions, including coiled-coil and structurally complex targets. Highly comparable to Coiled's approach against undruggable oncogenic proteins and its platform-based discovery model.
  • Black Diamond Therapeutics: Clinical-stage precision oncology company developing allosteric and mutation-targeted small molecules against historically difficult oncology targets. Comparable to Coiled in scale, development stage, and first-in-class precision oncology positioning.
  • Relay Therapeutics: Clinical-stage precision oncology company combining computational approaches with structure-based drug design against precision oncology targets, including protein motion-based design. Comparable to Coiled's AI/ML-driven design philosophy against complex targets.
  • Repare Therapeutics: Clinical-stage precision oncology company targeting synthetic lethal vulnerabilities in cancer using a platform-based discovery approach. Comparable in clinical-stage precision oncology positioning, multi-indication strategy, and platform-driven pipeline development.
  • Cogent Biosciences: Clinical-stage precision oncology company developing targeted therapies against oncogenic drivers with a focus on smaller, indication-focused trials and partnering optionality. Comparable to Coiled's clinical-stage, indication-specific development strategy.
  • Erasca: Clinical-stage precision oncology company developing small molecule inhibitors targeting the RAS/MAPK pathway. Comparable as a clinical-stage precision oncology peer with multiple programmes and a focus on historically difficult-to-drug oncogenic targets.

Broad incumbents

  • Schrödinger: Computational drug discovery company combining physics-based modelling with AI/ML for small molecule discovery across multiple therapeutic areas. Comparable to Coiled's use of computational and AI-driven drug design for structurally complex targets, though Schrödinger operates at much greater scale and breadth.
  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning for pharmaceutical R&D. Comparable to Coiled's AI/ML-driven discovery philosophy, though operating at much broader scale and across multiple therapeutic areas.
  • Exscientia: AI-driven precision medicine company using end-to-end AI platforms for small molecule drug discovery. Comparable to Coiled's AI/ML-driven de novo design approach, though Exscientia operates at greater scale with broader pipeline and partner network.

Emerging players

  • Alnylam Pharmaceuticals: Leading siRNA therapeutics company with multiple approved and clinical-stage RNA interference products across rare and specialty diseases. Comparable to Coiled's STAT-6 siRNA programme as the most established peer in the siRNA modality space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Coiled Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Coiled Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Coiled Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Coiled Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coiled Therapeutics

What does Coiled Therapeutics do?

Coiled Therapeutics is a clinical-stage precision oncology company developing first-in-class therapeutics targeting TACC3 and STAT-6 for high-risk cancers and inflammatory diseases. Its lead asset AO-252 is an oral brain-penetrant small molecule TACC3 inhibitor currently in Phase I clinical trials (NCT06136884) for solid tumors including ovarian, breast, prostate, lung, gastric, endometrial, sarcoma, and bladder cancers. The pipeline is supported by the proprietary SCULPT AI/ML-driven de novo drug design platform licensed from A2A Pharmaceuticals.

Is Coiled Therapeutics a public or private company?

Coiled Therapeutics is a public company. It is classified as public and is currently operating.

When was Coiled Therapeutics founded?

Coiled Therapeutics was founded in 2025. It employs 1 to 10 people.

Where is Coiled Therapeutics based?

Coiled Therapeutics is headquartered in London, United Kingdom, in the Europe region.

How does Coiled Therapeutics make money?

One revenue line is on record: pre-Revenue / Pipeline Development.

Who are Coiled Therapeutics's main competitors?

Direct peers on record are Foghorn Therapeutics, Black Diamond Therapeutics, Relay Therapeutics, Repare Therapeutics, Cogent Biosciences and Erasca. Broad incumbents are Schrödinger, Recursion Pharmaceuticals and Exscientia. Alnylam Pharmaceuticals is listed as an emerging player.

Does Coiled Therapeutics have an API?

No public API is recorded for Coiled Therapeutics.

What industry is Coiled Therapeutics in?

Coiled Therapeutics's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAAAIAH, Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InvestegateParticipation in The Small Cap ShowcaseCoiled Therapeutics will have its executive management team present at The Small Cap Showcase in New York City on 1 October 2026. Chairman Sotirios Stergiopoulos and non-executive director Stephen West will present the company's strategy and outlook, with a live webcast available. The event connects micro- and small-cap companies with institutional investors.Investing.comCoiled Therapeutics completes enrollment in AO-252 trial cohorts By Investing.comCoiled Therapeutics completed enrollment in two dose cohorts of its AO-252 cancer treatment, enrolling six patients in a Phase I trial. The new lipid-based softgel formulation follows a tablet version that showed an 80% clinical benefit rate in five patients. The company expects to dose up to 30 patients by end of 2026.InvestegateSuccessful Enrolment Completed Across Two CohortsCoiled Therapeutics completed enrolment of three patients each in 120mg twice-daily and 160mg once-daily cohorts of its new lipid-based softgel formulation of AO-252, a TACC3 inhibitor. The company expects to dose up to 30 patients with the new formulation by end of 2026, with initial safety and pharmacokinetic data readouts anticipated by then.TradingViewCOIL Stock Price and Chart — LSE:COIL — TradingViewCoiled Therapeutics Plc stock (COIL) is trading at 9.50 GBX, reflecting a 5.26% decrease over the past 24 hours and a broader decline across weekly, monthly, and yearly periods. The company reported a net income loss of -2.87 million GBP for the last half-year and maintains a market capitalization of 38.41 million GBP with no dividend payments.AInvestCoiled's 80% Signal Looks Real-But the Real Money Question Is Dilution vs. Dual-Indication ProofCoiled's AO-252 trial demonstrated an 80% clinical benefit rate with twice-daily dosing, doubling the 40% rate seen with once-daily dosing in 21 evaluable patients out of 31 enrolled, suggesting improved target engagement against a validated oncology target. The company completed an £8.5 million fundraise through the issuance of 85 million new ordinary shares, extending runway but raising dilution concerns that now weigh on the stock's catalyst-driven narrative. Coiled has identified prostate and ovarian cancers as planned expansion cohorts for 2026, with material readouts expected to determine whether the dosing signal translates into a durable development program or remains a binary biotech bet.YahooCoiled Therapeutics develops improved formulation of experimental cancer drug ahead of trial expansionCoiled Therapeutics, a clinical-stage oncology company listed on AIM, has developed a new lipid-based softgel formulation of its experimental cancer drug AO-252 designed to improve drug absorption, with the first patient dosing expected this month. The reformulation addresses limitations of the current tablet, which struggles to deliver the drug consistently at higher doses, and follows encouraging early clinical data showing an 80% clinical benefit rate in patients taking the drug twice daily versus 40% for once-daily dosing. The company plans to enroll up to 30 patients in targeted dose expansion cohorts for ovarian and prostate cancer by the fourth quarter of 2026, with fuller data expected in the second half of that year.Investing.comCoiled Therapeutics develops new formulation for AO-252 By Investing.comCoiled Therapeutics announced development of a lipid-based softgel formulation of its TACC3 inhibitor AO-252, with first patient dosing expected this month, aiming to address dose-dependent absorption limitations in the current tablet formulation. Phase I clinical data showed an 80% Clinical Benefit Rate in patients receiving twice-daily dosing versus 40% for once-daily dosing, with tumor reductions observed in ovarian and endometrial cancer patients. The company plans targeted dose expansion cohorts in ovarian and prostate cancer with enrollment targets of up to 30 patients by Q4 2026 and comprehensive data readouts anticipated in H2 2026.YahooCoiled Therapeutics develops improved formulation of experimental cancer drug ahead of trial expansionCoiled Therapeutics developed a lipid-based softgel formulation of its lead cancer drug AO-252 to improve absorption, with the first patient dosed this month. The reformulation follows Phase I data showing an 80% clinical benefit rate versus 40% for once-daily dosing. The company plans to enroll up to 30 patients in ovarian and prostate cancer cohorts by Q4 2026.ProactiveinvestorsCoiled Therapeutics recruits oncology heavyweights to advise on lead cancer drugCoiled Therapeutics, a clinical-stage oncology company listed on London's AIM market, has appointed Professor Guru Sonpavde and Dr Alexander Spira to a newly formed medical advisory board to guide its lead drug candidate AO-252 through early-stage Phase I human trials. AO-252 targets TACC3, a protein linked to cancer cell growth that currently has no validated therapy, and the appointments follow encouraging early clinical signals. The advisors will shape clinical strategy including expansion cohort design, indication selection, and combination therapy plans, with progression to an expansion phase anticipated in the second half of 2026.YahooCoiled Therapeutics begins trading on US OTCQB market to broaden investor baseCoiled Therapeutics began trading on the US OTCQB Venture Market under ticker COTXF, with shares jumping 25% to 11p. The cross-listing lets US investors trade in dollars, and the company will continue AIM trading under COIL. CEO Sridhar Vempati cited an 80% clinical benefit rate in a trial and expects dose escalation completion in H1 2026.